01767nas a2200385   4500000000100000008004100001260001300042653001000055653002200065653002500087653002900112653001100141653002300152653002300175653001000198653001100208653001200219653001100231653000900242653001700251100001500268700001500283700001200298700001400310700001400324700001900338700001800357700001400375700001800389245012500407300001000532490000800542520081700550022001401367       1995                            d  c1995 Aug10aAdult10aAntibodies, Viral10aCase-Control Studies10aFalse Positive Reactions10aFemale10aHIV Seronegativity10aHIV Seropositivity10aHIV-110aHumans10aleprosy10aMalawi10aMale10aTuberculosis1 aSterne J A1 aTurner A C1 aFine PE1 aParry J V1 aLucas S B1 aPonnighaus J M1 aMkandwire P K1 aNyasulu S1 aWarndorff D K00aTesting for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic.  a543-60 v1723 a<p>During a large epidemiologic study in the Karonga District of northern Malawi, serum samples from 139 patients with incident leprosy, 124 with newly diagnosed leprosy, 277 patients with incident tuberculosis, and 2296 controls were tested for antibodies to human immunodeficiency virus. Sera were tested according to a four-test protocol using two ELISAs and two particle agglutination assays. Overall, 188 samples were considered positive, 2634 were considered negative, and 14 were indeterminate. All 18 available positive specimens from leprosy patients, a random sample of 14 positive specimens from tuberculosis patients, and 15 positive specimens from controls were tested by Western blot. There was no evidence of substantial numbers of ELISA false-positives in any patient group or among controls.</p>  a0022-1899